Monocyte Plasminogen Activator Inhibitor 2 (PAI-2) Inhibits u-PA-mediated Fibrin Clot Lysis and Is Cross-linked to Fibrin

Summary

Plasminogen activator inhibitor 2 (PAI-2) is a major product of activated human monocytes. Here we show that monocytes inhibited u-PA- but not t-PA-mediated fibrinolysis, by secreting PAI-2 into an overlying fibrin clot. Extracts of arterial and venous human thrombi were found to contain active PAI-2. PAI-2 was cross-linked to fibrin in a reaction catalyzed by two major transglutaminases (TG), tissue TG and factor XIII. The activity of PAI-2 was not affected by such cross-linking. Cross-linking of PAI-2 to fibrin was inhibited by Tridegin, a specific inhibitor of TG, and also by EDTA and iodoacetamide. The use of competitive peptides mimicking the loop between helices C and D of PAI-2 identified Gln 83 and 86 as residues important in cross-linking. This study defines a mechanism by which PAI-2 is localized to fibrin, where it acts as an effective inhibitor of u-PA-mediated fibrinolysis.

 

• References

• 1 Booth NA. Natural inhibitors of fibrinolysis. In: Haemostasis and Thrombosis.. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. 3rd edn. Churchill Livingstone; 1994: pp 699-717.
• 2 Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19.
• 3 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
• 4 Lupu F, Heim D, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
• 5 Robbie LA, Booth NA, Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539-45.
• 6 Robbie LA, Bennett B, Croll AM, Brown PAJ, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75: 127-33.
• 7 Robbie LA, Wright GA, Booth NA, Bennett B. Inhibitors of fibrinolysis in normal and diseased human arteries. Thromb Haemost 1997; Suppl PS-2277 (abstr)
• 8 Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachman F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987; 69: 460-8.
• 9 Lyon S-G, iordano B, Loskutoff D, Chen C-S, Lazurus G, Keeton M, Jensen PJ. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochem 1994; 101: 105-12.
• 10 Whawell SA, Vipond MN, Scott-Combes DM, Thompson JN. Plasminogen activator inhibitor 2 reduces peritoneal activity in inflammation. Br J Surg 1993; 80: 107-9.
• 11 Astedt B, Hagerstrand I, Lecander I. Cellular localization in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 1986; 56: 63-9.
• 12 Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-24.
• 13 Remold O'Donnell E. The ovalbumin family of serpin proteins. FEBS Lett 1995; 315: 105-8.
• 14 Zoellner H, Wojta J, Gallicchio M, McGrath K, Hamilton JA. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. Thromb Haemost 1993; 69: 135-40.
• 15 Pytel BA, Peppel K, Baglioni C. Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumor necrosis factor. J Cell Physiol 1990; 144: 416-22.
• 16 Ritchie H, Jamieson A, Booth NA. Thrombin modulates synthesis of plasminogen activator inhibitor 2 (PAI-2) by human peripheral blood monocytes. Blood 1995; 86: 3428-35.
• 17 Ritchie H, Booth NA. Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum-Golgi-independent pathway. Exp Cell Res 1998; 242: 439-50.
• 18 Kirchheimer JC, Remold HG. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 1989; 74: 1396-1402.
• 19 Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-4.
• 20 Gan H, Newman GW, Remold HG. Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4. J Immunol 1995; 155: 1304-15.
• 21 Dickinson JL, Bates EJ, Ferrante A, Antalis T. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor α-induced apoptosis. J Biol Chem 1995; 270: 27894-904.
• 22 Jensen PH, Schuler E, Woodrow G, Richardson M, Goss N, Hujrup P, Petersen TE, Rasmussen LK. A unique interhelical insertion in plasmino-gen activator inhibitor-2 contains three glutamines, Gln83, Gln84, Gln86, essential for transglutaminase-mediated cro-linking. J Biol Chem 1994; 269: 15394-8.
• 23 Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2 plasminogen activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIatransglutaminase-catalyzed cross linking to cellular and extracellular structures. Eur J Biochem 1993; 214: 141-6.
• 24 Jensen PJ, Wu Q, Janowitz P Ando Y, Schechter NM. Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp Cell Res 1995; 217: 65-72.
• 25 Aeschlimann D, Paulsson M. Transglutaminases: protein cro-linking enzymes in tissues and body fluids. Thromb Haemost 1994; 71: 402-15.
• 26 Gorman JJ, Folk JE. Structural features of glutamine substrates for tranS-glutaminases. J Biol Chem 1981; 256: 2712-6.
• 27 Sakata Y, Aoki N. Significance of cro-linking of α₂-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
• 28 Greenberg CS, Achyuthan KE, Borowitz MJ, Shuman MA. The transglutaminase in vascular cells and tissues could provide an alternative pathway for fibrin stabilization. Blood 1987; 70: 702-8.
• 29 Robbie LA, Booth NA, Croll AM, Bennett B. The roles of α₂-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-6.
• 30 Booth NA, MacGregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from endothelial cells. Purification and partial characterization. Eur J Biochem 1987; 165: 595-600.
• 31 Sancho ES, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli . Eur J Biochem 1994; 224: 125-31.
• 32 Steven J, Cottingham IR, Berry SJ, Chinery SA, Goodey AR, Courtney M, Ballance DJ. Purification and characterisation of plasminogen activator inhibitor 2 produced in Saccharomyces cerevisiae . Eur J Biochem 1991; 196: 431-8.
• 33 Reith A, Bennett B, Booth NA. Plasminogen activator inhibitor (PAI-2) in pregnancy plasma and ovarian cysts, studied by zymography after non denaturing gel electrophoresis. Fibrinolysis 1989; 3: 159-63.
• 34 Finney S, Seale L, Sawyer RT, Wallis RB. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood sucking leech, Haementeria ghilianii. . Biochem J 1997; 324: 797-805.
• 35 Raut S, Gaffney P. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies. Thromb Haemost 1996; 76: 56-64.
• 36 Ritchie H, Jamieson A, Booth NA. Regulation, location and activity of plasminogen activator inhibitor 2 (PAI-2) in peripheral blood monocytes, macrophages and foam cells. Thromb Haemost 1997; 77: 1168-73.
• 37 Leung K-C, Byatt JA, Stephens RW. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (Minactivin). Thromb Res 1987; 46: 755-66.
• 38 Lijnen HR, Bachmann F, Collen D, Ellis V, Pannekoek H, Rijken DC, Thorsen S. Mechanisms of plasminogen activation. J Int Med 1994; 236: 415-20.
• 39 Ellis V, Pyke C, Eriksen J, Solberg H, Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992; 13-8.
• 40 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
• 41 Hettasch JM, Haroon ZA, Lai TS, Slaughter TF, Greenberg CS. Tissue transglutaminase as a wound healing enzyme that triggers platelet activation. Thromb Haemost 1997; Suppl PS-1439 (abstr)
• 42 Tamaki T, Aoki N. Cro-linking of α₂-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
• 43 Gruther MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9: 2361-5.
• 44 Seale L, Finney S, Sawyer RT, Wallis RB. Tridegin, a novel inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis. Thromb Haemost 1997; 77: 959-63.
• 45 Genton C, Kruithof EKO, Schleuning W-D. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in human U937 lymphoma cells. J Cell Biol 1987; 104: 705-12.
• 46 Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-6.